In Switzerland, the pharmaceutical industry is facing significant challenges as Takeda, a Japanese company based in Opfikon, plans to cut up to 120 jobs. The consultation process for mass layoffs has begun and is expected to be completed by June 14, 2024. Employees will be informed of the outcome on June 17th.
While the number of job cuts may change, employees at Takeda’s headquarters in Opfikon are likely to experience significant reductions. With approximately 1,200 employees and another 650 at a production plant in Neuenburg, Takeda is one of the major employers in the Swiss pharmaceutical industry. However, due to restructuring as part of a global efficiency program aimed at improving profitability, the company is undergoing major changes.
The restructuring plan will span several years and involve reducing management functions by flattening the organization. Takeda has budgeted $900 million for this effort and it will impact operations worldwide. The Opfikon location houses over 20 corporate functions, including managing production sites globally and European business activities. Additionally, reports indicate that almost 500 jobs will be eliminated at Takeda’s operations in Cambridge, Massachusetts which support the US market.
Takeda aims to streamline its operations while improving efficiency and minimizing costs through this restructuring effort. The Swiss pharmaceutical industry is closely watching this situation with interest as it could have wider implications for other companies operating within it.
